Revised response criteria for malignant lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, Randy D. Gascoyne, Lena Specht, Sandra J. Horning, Bertrand Coiffier, Richard I. Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T. Rosen, Sigrid Stroobants, T. Andrew Lister, Richard T. Hoppe, Martin Dreyling, Kensei Tobinai, Julie M. Vose, Joseph M. Connors, Massimo Federico, Volker Diehl

Research output: Contribution to journalReview article

2968 Citations (Scopus)

Abstract

Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F] fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

Original languageEnglish (US)
Pages (from-to)579-586
Number of pages8
JournalJournal of Clinical Oncology
Volume25
Issue number5
DOIs
StatePublished - Feb 10 2007

Fingerprint

Positron-Emission Tomography
Lymphoma
Flow Cytometry
Immunohistochemistry
Guidelines
Fluorodeoxyglucose F18
Biotechnology
Hodgkin Disease
Non-Hodgkin's Lymphoma
Clinical Trials
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., ... Diehl, V. (2007). Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25(5), 579-586. https://doi.org/10.1200/JCO.2006.09.2403

Revised response criteria for malignant lymphoma. / Cheson, Bruce D.; Pfistner, Beate; Juweid, Malik E.; Gascoyne, Randy D.; Specht, Lena; Horning, Sandra J.; Coiffier, Bertrand; Fisher, Richard I.; Hagenbeek, Anton; Zucca, Emanuele; Rosen, Steven T.; Stroobants, Sigrid; Lister, T. Andrew; Hoppe, Richard T.; Dreyling, Martin; Tobinai, Kensei; Vose, Julie M.; Connors, Joseph M.; Federico, Massimo; Diehl, Volker.

In: Journal of Clinical Oncology, Vol. 25, No. 5, 10.02.2007, p. 579-586.

Research output: Contribution to journalReview article

Cheson, BD, Pfistner, B, Juweid, ME, Gascoyne, RD, Specht, L, Horning, SJ, Coiffier, B, Fisher, RI, Hagenbeek, A, Zucca, E, Rosen, ST, Stroobants, S, Lister, TA, Hoppe, RT, Dreyling, M, Tobinai, K, Vose, JM, Connors, JM, Federico, M & Diehl, V 2007, 'Revised response criteria for malignant lymphoma', Journal of Clinical Oncology, vol. 25, no. 5, pp. 579-586. https://doi.org/10.1200/JCO.2006.09.2403
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology. 2007 Feb 10;25(5):579-586. https://doi.org/10.1200/JCO.2006.09.2403
Cheson, Bruce D. ; Pfistner, Beate ; Juweid, Malik E. ; Gascoyne, Randy D. ; Specht, Lena ; Horning, Sandra J. ; Coiffier, Bertrand ; Fisher, Richard I. ; Hagenbeek, Anton ; Zucca, Emanuele ; Rosen, Steven T. ; Stroobants, Sigrid ; Lister, T. Andrew ; Hoppe, Richard T. ; Dreyling, Martin ; Tobinai, Kensei ; Vose, Julie M. ; Connors, Joseph M. ; Federico, Massimo ; Diehl, Volker. / Revised response criteria for malignant lymphoma. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 5. pp. 579-586.
@article{75450de398794f5fbed8b7e413e0d50a,
title = "Revised response criteria for malignant lymphoma",
abstract = "Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F] fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.",
author = "Cheson, {Bruce D.} and Beate Pfistner and Juweid, {Malik E.} and Gascoyne, {Randy D.} and Lena Specht and Horning, {Sandra J.} and Bertrand Coiffier and Fisher, {Richard I.} and Anton Hagenbeek and Emanuele Zucca and Rosen, {Steven T.} and Sigrid Stroobants and Lister, {T. Andrew} and Hoppe, {Richard T.} and Martin Dreyling and Kensei Tobinai and Vose, {Julie M.} and Connors, {Joseph M.} and Massimo Federico and Volker Diehl",
year = "2007",
month = "2",
day = "10",
doi = "10.1200/JCO.2006.09.2403",
language = "English (US)",
volume = "25",
pages = "579--586",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Revised response criteria for malignant lymphoma

AU - Cheson, Bruce D.

AU - Pfistner, Beate

AU - Juweid, Malik E.

AU - Gascoyne, Randy D.

AU - Specht, Lena

AU - Horning, Sandra J.

AU - Coiffier, Bertrand

AU - Fisher, Richard I.

AU - Hagenbeek, Anton

AU - Zucca, Emanuele

AU - Rosen, Steven T.

AU - Stroobants, Sigrid

AU - Lister, T. Andrew

AU - Hoppe, Richard T.

AU - Dreyling, Martin

AU - Tobinai, Kensei

AU - Vose, Julie M.

AU - Connors, Joseph M.

AU - Federico, Massimo

AU - Diehl, Volker

PY - 2007/2/10

Y1 - 2007/2/10

N2 - Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F] fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

AB - Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F] fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=33947496614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947496614&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.09.2403

DO - 10.1200/JCO.2006.09.2403

M3 - Review article

C2 - 17242396

AN - SCOPUS:33947496614

VL - 25

SP - 579

EP - 586

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -